Ambien Data Supports Long Term Use

Sanofi-aventis today announced results from a study that demonstrated AMBIEN CR is well-tolerated and effective in improving sleep onset and maintenance for up to six months in patients with chronic primary insomnia when taken as needed for up to seven nights per week, without rebound insomnia following discontinuation. These data are being presented on July 12 in Chicago at the CINP (Collegium Internationale Neuro- Psychopharmacologicum) 25th Biennial Congress, a meeting ground for clinicians and scientists to report new scientific evidence in biochemistry, pharmacology, safety, and therapeutic efficacy of neuropsychiatric prescription drugs.

Click Here To Buy Ambien Online

According to the data, AMBIEN CR demonstrated significant improvements in total sleep time (TST), sleep onset latency (SOL), wake time after sleep onset (WASO), sleep quality, and number of awakenings versus placebo. AMBIEN CR is the first and only controlled release prescription sleep medicine approved by the FDA for sleep induction and sleep maintenance.

“These data are important for patients who experience chronic insomnia because they demonstrate there is a treatment option in AMBIEN CR that can be taken safely and effectively as needed long-term to help them both fall asleep and maintain sleep through the night,” said Tom Roth, PhD, director, Sleep Disorders Center, Henry Ford Hospital.